• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Cardiovascular Risk Reduction Tools

Article

A cardiovascular risk reference guide, Framingham global risk assessment scoring guide, cardiovascular checklist, and cardiovascular risk-reduction treatment plan.

Cardiovascular Risk Reference Guide

Patient's name________________________________________________________
Chart #______________
Date___________________
Please complete pages 1, 2, and 3 during the patient's first office visit. Place in front of the patient's chart.

CARDIOVASCULAR RISK FACTORS
Nonmodifiable

Modifiable

ORGAN DAMAGE ASSESSMENT

HYPERTENSION ASSESSMENT
Identifiable causes of hypertension or secondary hypertension (when indicated)

OTHER ASSESSMENTS

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Related Content
More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

Grace Halsey
November 21st 2024
Article

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock

GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose

Sydney Jennings
November 14th 2024
Article

Your daily dose of the clinical news you may have missed.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity / Image credit: ©missbobbit/AdobeStock

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity

Sydney Jennings
November 6th 2024
Article

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity / image credit Steven J Nicholls, MBBS, PhD, Monash University Melbourne, Australia

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity

Grace Halsey
November 5th 2024
Article

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

© 2024 MJH Life Sciences

All rights reserved.